EXACTA · UNITED STATES
Angiogenesis inhibitor combination study
Crook T and colleagues • Frontiers in Molecular Medicine • 2021
- DOI
- 10.3389/fmmed.2021.749283
- Design
- Analysis of profiling-informed combination regimens in advanced refractory cancers.
- Population
- 60 patients.
- Endpoints
- Objective response, disease control, progression-free survival, and overall survival.
- Reported results
- 28/60 had a partial response (46.7%); median progression-free survival was 5.0 months and overall survival 8.9 months.
- Limitations
- Heterogeneous, nonrandomized cohort; no concurrent randomized comparator. Results cannot establish a causal benefit from testing.
- Funding and conflicts
- Funded by Datar Cancer Genetics; company employment and founder relationships are disclosed in the paper.